Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00602667 · OUTCOME

Percent of Patients With Sustained Objective Responses Rate After Consolidation

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
8 weeks after completion of consolidation therapy (up to 8 months after on-study date)

What was measured

For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.

Analysis population: Of the 50 high-risk patients that started consolidation chemotherapy, 38 had measurable residual disease after induction and were included in this result.

Groups in this outcome

High-Risk Group

Patients with central nervous system (CNS) metastatic disease

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High-Risk Group38

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
High-Risk Group13.2Not reported4.428.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.4
        upper Limit
        28.1
        value
        13.2
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    units
    Participants
description
For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients with central nervous system (CNS) metastatic disease
    id
    OG000
    title
    High-Risk Group
param Type
NUMBER
population Description
Of the 50 high-risk patients that started consolidation chemotherapy, 38 had measurable residual disease after induction and were included in this result.
reporting Status
POSTED
time Frame
8 weeks after completion of consolidation therapy (up to 8 months after on-study date)
title
Percent of Patients With Sustained Objective Responses Rate After Consolidation
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice